Evidence map›Paper›PMID 39289525›Full record

ArticleJournal of human genetics2025

Nationwide survey of the secondary findings in cancer genomic profiling: survey including liquid biopsy.

Saki Shimada, Takahiro Yamada, Akari Minamoto, Manami Matsukawa, Ichiro Yabe, Hiroshi Tada, Katsutoshi Oda, Arisa Ueki, Satomi Higashigawa, Maki Morikawa and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of human genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Saki ShimadaDepartment of Medical Ethics and Medical Genetics, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID http://orcid.org/0000-0001-9249-2409
Takahiro YamadaDepartment of Medical Ethics and Medical Genetics, Kyoto University Graduate School of Medicine, Kyoto, Japan. taka0197@med.hokudai.ac.jp.ORCID http://orcid.org/0000-0002-5370-7873
Akari MinamotoClinical Genetics Unit, Kyoto University Hospital, Kyoto, Japan.
Manami MatsukawaDepartment of Medical Ethics and Medical Genetics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Ichiro YabeDivision of Clinical Genetics, Hokkaido University Hospital, Sapporo, Japan.ORCID http://orcid.org/0000-0002-1734-7997
Hiroshi TadaSecondary Findings Working Group (SFWG), Liaison Council for Core Hospitals for Cancer Genomic Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0003-2670-8982
Katsutoshi OdaSecondary Findings Working Group (SFWG), Liaison Council for Core Hospitals for Cancer Genomic Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0002-2468-9573
Arisa UekiSecondary Findings Working Group (SFWG), Liaison Council for Core Hospitals for Cancer Genomic Medicine, Tokyo, Japan.
Satomi HigashigawaSecondary Findings Working Group (SFWG), Liaison Council for Core Hospitals for Cancer Genomic Medicine, Tokyo, Japan.
Maki MorikawaSecondary Findings Working Group (SFWG), Liaison Council for Core Hospitals for Cancer Genomic Medicine, Tokyo, Japan.
Yuki SatoSecondary Findings Working Group (SFWG), Liaison Council for Core Hospitals for Cancer Genomic Medicine, Tokyo, Japan.
Akira HirasawaSecondary Findings Working Group (SFWG), Liaison Council for Core Hospitals for Cancer Genomic Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0003-4124-5488
Masanobu OgawaDepartment of Medical Ethics and Medical Genetics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Tomohiro KondoSecondary Findings Working Group (SFWG), Liaison Council for Core Hospitals for Cancer Genomic Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0001-5102-2654
Masahiro YoshiokaSecondary Findings Working Group (SFWG), Liaison Council for Core Hospitals for Cancer Genomic Medicine, Tokyo, Japan.
Masashi KanaiSecondary Findings Working Group (SFWG), Liaison Council for Core Hospitals for Cancer Genomic Medicine, Tokyo, Japan.
Manabu MutoDepartment of Medical Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Shinji KosugiDepartment of Medical Ethics and Medical Genetics, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID http://orcid.org/0000-0001-6036-6491

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We surveyed the status of the secondary finding (SF) disclosure in comprehensive genome profiling (CGP) in 2020. The situation has changed: increase in the number of hospitals that provide CGP, an update to the Comprehensive Tumor Genomic Profiling: Materials for Review of Secondary Findings (CTGPMRSF), and the addition of a liquid biopsy test, FoundationOne

Indexed as

GenomicsNeoplasmsBiomarkers, TumorGenetic TestingHospitalsHumansLiquid BiopsySurveys and QuestionnairesBiomarkers, Tumor

Identifiers

PMID39289525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.